|
市場調查報告書
精神病治療藥的藥價設定及償付環境
Pricing and Reimbursement Issues in Psychiatry
|
本報告已在2011年12月21日停止出版。
與癌症免疫疾病等其他疾病相比，精神病的藥物治療費用並不是那麼龐大。但是根據WHO的預測，到2020年為止 精神病當中的憂鬱症將成為全球第2大死因及身心傷殘的原因，形成先進國家最大的問題。
專門於醫療產業相關廣泛調查的美國市調公司 Decision Resources Inc. （總公司：麻薩諸塞州），針對精神病治療藥的藥價制定及償付環境進行調查分析，並系統整理調查結果後出版報告書 "Pricing and Reimbursement Issues in Psychiatry" 。
本報告書內容包括：精神病治療藥等級介紹，以及美國、法國、德國、義大利、西班牙、英國和日本等個別市場的趨勢及藥價比較、償付趨勢、未來市場發展前景預測等。共計44頁的內容綱要摘記如下：
實施概要
序章
精神病治療藥的國際的藥價比較
- 概要
- 抗憂鬱症藥
- 抗精神病藥
- 精神刺激藥
- 安眠藥、止痛劑、抗不安藥
償付環境
美國
- 整體環境
- 民間保險
- Medicare
- medicaid
- 抗憂鬱症藥
- 抗精神病藥
- 精神刺激藥
- 安眠藥、止痛劑、抗不安藥
法國
- 整體環境
- 抗憂鬱症藥
- 抗精神病藥
- 精神刺激藥
- 安眠藥、止痛劑、抗不安藥
德國
- 整體環境
- 抗憂鬱症藥
- 抗精神病藥
- 精神刺激藥
- 安眠藥、止痛劑、抗不安藥
義大利
- 整體環境
- 抗憂鬱症藥
- 抗精神病藥
- 精神刺激藥
- 安眠藥、止痛劑、抗不安藥
西班牙
- 整體環境
- 抗憂鬱症藥
- 抗精神病藥
- 精神刺激藥
- 安眠藥、止痛劑、抗不安藥
英國
- 整體環境
- 抗憂鬱症藥
- 抗精神病藥
- 精神刺激藥
- 安眠藥、止痛劑、抗不安藥
Abstract
Introduction
Compared with many other disease areas (e.g., cancer, immune diseases), the
costs of drug therapy for psychiatric disorders are relatively modest.
However, the World Health Organization forecasts that by 2020, depression-just
one of a spectrum of psychiatric disorders-will be the second most frequent
cause of death and disability in the world and the leading cause in
industrialized nations. In anticipation of this surge, payers in the major
pharmaceutical markets would like to exercise greater control over the use of
psychiatric drugs.
Get the Answers You Need to Shape Your Strategy
In just the major pharmaceutical markets, the number of people affl icted with
common psychiatric disorders will increase, and spending on drug therapies
will grow steadily. How will payers try to curb spending on psychiatric
drugs? The prices of generic antidepressants are much higher in Europe
than in the United States. What factors are behind this differential?
Pharmacy benefits offered by U.S. private insurers tend to be considerably
more generous than the coverage provided by Medicare and Medicaid, but
cost-containment measures are proliferating. What steps are private
insurers taking to control drug expenditures? Medicare Part D offers
outpatient drug coverage to all Medicare beneficiaries who choose to enroll.
What will be the standard benefi t design of Part D in 2007? The U.S.
Medicaid program is a major source of funding for psychiatric drugs-especially
atypical antipsychotics. What cost-cutting measures are state Medicaid
programs instituting to control drug expenditures? France has the lowest
average prices of any of the major pharmaceutical markets for branded
antidepressants. Nevertheless, the government would like to reduce spending on
this drug class. What steps has the Caisse Nationale de l' Assurance Maladie
taken to stimulate France' s relatively immature generics market? How
successful have these measures been so far?
Scope
- Drug classes covered: antidepressants, antipsychotics,
psychostimulants, hypnotics, sedatives, and anxiolytics.
- Markets covered: United States, France, Germany, Italy, Spain,
United Kingdom, and Japan.
- Price comparisons: comparisons of international pricing of the
psychiatric drug classes in this report.
- Reimbursement: overview of the general environment in each market
and analysis of factors specific to individual psychiatric drug classes.
- Market outlook: pricing and reimbursement implications for the
manufacturers of psychiatric drugs.
Mentioned in This Spectrum Report
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- International Price Comparisons of Psychiatric Drugs
- Overview
- Antidepressants
- Antipsychotics
- Psychostimulants
- Hypnotics, Sedatives, and Anxiolytics
- Reimbursement Environment
- United States
- General Environment
- Private Insurance
- Medicare
- Sidebar: Patient Assistance Programs-An Important Source of Drug Funding
- Medicaid
- Antidepressants
- Antipsychotics
- Psychostimulants
- Hypnotics, Sedatives, and Anxiolytics
- France
- General Environment
- Antidepressants
- Antipsychotics
- Psychostimulants
- Hypnotics, Sedatives, and Anxiolytics
- Germany
- General Environment
- Antidepressants
- Antipsychotics
- Psychostimulants
- Hypnotics, Sedatives, and Anxiolytics
- Italy
- General Environment
- Antidepressants
- Antipsychotics
- Psychostimulants
- Hypnotics, Sedatives, and Anxiolytics
- Spain
- General Environment
- Antidepressants
- Antipsychotics
- Psychostimulants
- Hypnotics, Sedatives, and Anxiolytics
- United Kingdom
- General Environment
- Antidepressants
- Antipsychotics
- Psychostimulants
- Hypnotics, Sedatives, and Anxiolytics
|
